NEKTAR THERAPEUTICS (NKTR) Return on equity 2016–2025
NEKTAR THERAPEUTICS (NKTR) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-182.6%FY2025 · since FY2016: -174.2% → -182.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -182.6% | +13.4 pp |
| FY2024 | -195.9% | +14.8 pp |
| FY2023 | -210.7% | -110.3 pp |
| FY2022 | -100.4% | -23.3 pp |
| FY2021 | -77.1% | -35.9 pp |
| FY2020 | -41.3% | -9.9 pp |
| FY2019 | -31.4% | -71.0 pp |
| FY2018 | 39.7% | +149.8 pp |
| FY2017 | -110.1% | +64.1 pp |
| FY2016 | -174.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice